1. Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group

   • Paola Perego
   • Georg Hempel
   • On behalf of the EORTC PAMM Group

   Review Article 28 December 2017 Pages: 427 - 441

   

2. First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

   • Shuyun Wang
   • Aiqin Gao
   • Yuping Sun

   Review Article 11 January 2018 Pages: 443 - 453

3. Pharmacokinetics of dacarbazine (DTIC) in pregnancy

   • Ira Kantrowitz-Gordon
   • Karen Hays
   • Mary F. Hebert

   Original Article 05 January 2018 Pages: 455 - 460

   

4. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202)

   • Hiroaki Yanagimoto
   • Hideyoshi Toyokawa
   • Tatsuya Ioka

   Original Article 05 January 2018 Pages: 461 - 468

   

5. Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma

   • Jingnan Wang
   • Zhirong Zhang
   • Jie He

   Original Article 08 January 2018 Pages: 469 - 481

   

6. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations

   • Nilsa Rivera-Del Valle
   • Tiewei Cheng
   • Joya Chandra

   Original Article 08 January 2018 Pages: 483 - 495

   

7. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer

   • Kathleen Moore
   • Zhi-Yi Zhang
   • Vikram Kansra

   Original Article Open access 10 January 2018 Pages: 497 - 503

   

8. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab

   • Francisco J. Esteva
   • Justin Stebbing
   • Sang Joon Lee

   Original Article Open access 12 January 2018 Pages: 505 - 514

   

9. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

   • Myrna Candelaria
   • Derlis Gonzalez
   • Susana Millán

   Original Article Open access 24 January 2018 Pages: 515 - 527

   

10. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors

    • John Nemunaitis
    • Annie Young
    • Albiruni Razak

    Original Article 24 January 2018 Pages: 529 - 537

    

11. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study

    • Hiroyuki Ohnuma
    • Yasushi Sato
    • Junji Kato

    Original Article 30 January 2018 Pages: 539 - 548

    

12. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma

    • Souichi Yanamoto
    • Masahiro Umeda
    • Iwai Tohnai

    Original Article 30 January 2018 Pages: 549 - 554

    

13. 2-Deoxy-d-glucose enhances TRAIL-induced apoptosis in human gastric cancer cells through downregulating JNK-mediated cytoprotective autophagy

    • Yuting Xu
    • Qingling Wang
    • Maojin Zheng

    Original Article 31 January 2018 Pages: 555 - 564

    

14. Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer

    • Tetsuhiko Taira
    • Kiyotaka Yoh
    • Koichi Goto

    Original Article 31 January 2018 Pages: 565 - 572

    

15. S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

    • Stine Braendegaard Winther
    • Jon Kroll Bjerregaard
    • Per Pfeiffer

    Original Article 31 January 2018 Pages: 573 - 578

    

16. Role of TPMT and ITPA variants in mercaptopurine disposition

    • Tina Gerbek
    • Maria Ebbesen
    • Kjeld Schmiegelow

    Original Article 01 February 2018 Pages: 579 - 586

    

17. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies

    • John F. Deeken
    • Hongkun Wang
    • Michael J. Pishvaian

    Original Article 01 February 2018 Pages: 587 - 596

    

18. Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

    • Steven Blotner
    • Lin-Chi Chen
    • Jianguo Zhi

    Original Article 01 February 2018 Pages: 597 - 607

    

19. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

    • Jacob E. Shabason
    • Jerry Chen
    • Edgar Ben-Josef

    Clinical Trial Report 23 January 2018 Pages: 609 - 614

    

20. Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs

    • Jessica Cusato
    • Lucio Boglione
    • Antonio D’Avolio

    Short Communication 22 January 2018 Pages: 615 - 620

21. A note on improved statistical approaches to account for pseudoprogression

    • Nacer Abrouk
    • Bryan Oronsky
    • Donna Peehl

    Short Communication 05 February 2018 Pages: 621 - 626

    

22. Retraction Note to: Quinoxaline 1,4-dioxides induce G₂/M cell cycle arrest and apoptosis in human colon cancer cells

    • Hala U. Gali-Muhtasib
    • Mona Diab-Assaf
    • Makhluf J. Haddadin

    Retraction Note 08 January 2018 Pages: 627 - 627